PD-1/PD-L1抑制剂在非小细胞肺癌临床治疗中的研究进展

Advances in PD-1/PD-L1 inhibitors in treatment of non-small cell lung cancer

摘要: 肺癌是引起肿瘤相关性死亡的首位疾病。非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的生存期在进入靶向治疗时代后得到了大幅延长,但晚期肺癌的预后仍亟待提高。近来,程序性死亡分子1(programmed death-1,PD-1)及其配体1(programmed death ligand-1,PD-L1)抑制剂在NSCLC的治疗中取得了重大突破。本文就PD-1/PD-L1抑制剂在NSCLC临床治疗中的现状及进展进行总结。

Abstract: Lung cancer is the leading cause of cancer-related deaths around the world. Although targeted therapy has significantly prolonged the survival of patients with non-small cell lung cancer (NSCLC), the prognosis of NSCLC remains unsatisfactory.Recently, immune checkpoint inhibitors of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have made a breakthrough in the treatment of NSCLC. This review aims to summarize the current status quo and prospect of immune checkpoint inhibitor PD-1/PD-L1 in treatment of NSCLC.